1 week Ago By Defense World Staff
Cerity Partners LLC bought a new stake in shares of Nuvation Bio Inc. (NYSE:NUVB – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 11,809 shares of the company’s stock, valued at approximately $31,000.
A number of other hedge funds have also made changes to their positions in NUVB. FMR LLC increased its holdings in Nuvation Bio by 54.9% in the fourth quarter.
FMR LLC now owns 45,285,572 shares of the company’s stock valued at $120,460,000 after buying an additional 16,046,701 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Nuvation Bio by 15,183.
7% in the 4th quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock valued at $42,000 after acquiring an additional 15,791 shares during the last quarter.
Wells Fargo & Company MN lifted its stake in Nuvation Bio by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 106,416 shares of the company’s stock worth $283,000 after purchasing an additional 23,178 shares during the last quarter.
Geode Capital Management LLC boosted its holdings in Nuvation Bio by 22.9% in the fourth quarter. Geode Capital Management LLC now owns 4,951,195 shares of the company’s stock worth $13,174,000 after purchasing an additional 922,503 shares during the period.
Finally, Wellington Management Group LLP increased its stake in Nuvation Bio by 8.3% during the fourth quarter. Wellington Management Group LLP now owns 676,024 shares of the company’s stock valued at $1,798,000 after purchasing an additional 52,051 shares during the last quarter.
Institutional investors and hedge funds own 61.67% of the company’s stock. Insiders Place Their BetsIn other news, CEO David Hung acquired 200,000 shares of the business’s stock in a transaction dated Friday, April 4th.
The stock was acquired at an average price of $1.66 per share, for a total transaction of $332,000.00.
Following the completion of the acquisition, the chief executive officer now directly owns 58,481,054 shares in the company, valued at $97,078,549.64. This represents a 0.
34 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 29.
93% of the stock is owned by insiders. Nuvation Bio Stock PerformanceShares of NUVB stock opened at $2.13 on Friday.
The firm has a market capitalization of $721.39 million, a PE ratio of -0.98 and a beta of 1.
47. The stock has a fifty day moving average of $1.95 and a two-hundred day moving average of $2.
37. Nuvation Bio Inc. has a 1 year low of $1.
54 and a 1 year high of $3.97. Wall Street Analysts Forecast GrowthNUVB has been the topic of a number of recent research reports.
Jones Trading initiated coverage on shares of Nuvation Bio in a research report on Wednesday, March 12th. They issued a “buy” rating and a $10.00 price target on the stock.
Citigroup began coverage on Nuvation Bio in a research note on Wednesday. They issued an “outperform” rating for the company. HC Wainwright dropped their price target on Nuvation Bio from $11.
00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Citizens Jmp initiated coverage on Nuvation Bio in a research report on Wednesday.
They set a “mkt outperform” rating and a $6.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $5.
00 target price on shares of Nuvation Bio in a research note on Thursday, March 27th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.
com, the company has an average rating of “Buy” and an average target price of $7.83.Get Our Latest Stock Report on Nuvation BioNuvation Bio Company Profile (Free Report)Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.Featured ArticlesFive stocks we like better than Nuvation BioWhy Are Stock Sectors Important to Successful Investing?Markets Think Robinhood Earnings Could Send the Stock UpWhy is the Ex-Dividend Date Significant to Investors?Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?Stock Average Calculator AT&T: Subscriber Growth & Buybacks Signal Bullish TurnaroundWant to see what other hedge funds are holding NUVB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvation Bio Inc.
(NYSE:NUVB – Free Report)..
